UK Markets open in 7 hrs 42 mins

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
84.85+0.84 (+1.00%)
At close: 11:28AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close84.01
Bid0.00 x 0
Ask0.00 x 0
Day's range82.10 - 84.91
52-week range78.78 - 95.00
Avg. volume23,911
Market cap190.132B
Beta (5Y monthly)0.55
PE ratio (TTM)19.60
EPS (TTM)4.33
Earnings dateN/A
Forward dividend & yield3.35 (3.87%)
Ex-dividend date08 Mar 2022
1y target estN/A
  • Reuters

    Novartis to cut up to 8,000 jobs globally

    ZURICH (Reuters) -Novartis said on Tuesday a previously announced restructuring programme could lead to 8,000 jobs being cut, or about 7.4% of its global workforce, including up to 1,400 in Switzerland. The job cuts, previously projected by Chief Executive Vas Narasimhan to be in the "single digit thousands", are part of a restructuring programme the Swiss pharmaceutical group announced in April, targeting savings of at least $1 billion by 2024. Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles across the organisation.

  • Zacks

    Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific

    Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).

  • Zacks

    Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

    The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.